Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts

A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO)

T. M. Schiele, E. Regar, S. Silber, E. Eeckhout, D. Baumgart, W. Wijns, A. Colombo, W. Rutsch, D. Meerkin, A. Gershlick, R. Bonan, P. Urban

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To assess clinically and angiographically the feasibility, safety, and effectiveness of vascular brachytherapy (VBT) in saphenous vein bypass grafts (SVG). Patients and methods: 67 of 1098 (6.1%) consecutive patients of the European registry of intraluminal coronary β brachytherapy underwent treatment for 68 SVG lesions by VBT using a Sr/Y90 source train (BetaCath). Clinical follow up data were obtained for all of them after a mean (SD) of 6.3 (2.4) months and angiographic follow up was performed in 61 patients (91.0%) after 6.9 (2.0) months. Results: 58 (86.6%) patients were men, their mean (SD) age was 66 (10) years, 28 (41.8%) had unstable angina, and 21 (31.3%) had diabetes. Fifty three (77.9%) lesions were in-stent restenosis, 13 (19.1%) de novo lesions, and 2 (3.0%) non-stented restenotic lesions. Mean (SD) reference diameter before the intervention was 4.19 (0.52) mm, mean (SD) lesion length was 23.56 (20.38) mm, and mean (SD) minimum lumen diameter measured 0.73 (0.62) mm. Mean (SD) acute gain was 3.02 (0.88) mm. The prescribed radiation dose was 20.1 (3.2) Gy. Pullback manoeuvres were performed in 17 (25.0%) of cases. Most patients received combined aspirin and thienopyridin treatment for 6 or 12 months after the procedure. Technical success was obtained in 62 (91.2%) treated lesions and in-hospital major adverse cardiac events occurred in 4.5%. At follow up, mean (SD) reference diameter was 4.20 (0.53) mm, minimum lumen diameter 2.94 (1.50) mm, and late loss 0.86 (1.25) mm. The overall major adverse cardiac events rate was 26.7%. Conclusion: VBT of SVG is feasible and safe. At follow up the reintervention rate and cardiac morbidity and mortality seem to be favourable, considering that interventions in SVG usually are associated with the highest risks.

Original languageEnglish
Pages (from-to)640-644
Number of pages5
JournalHeart
Volume89
Issue number6
Publication statusPublished - Jun 1 2003

Fingerprint

Saphenous Vein
Brachytherapy
Registries
Transplants
Blood Vessels
Unstable Angina
Aspirin
Stents
Radiation
Morbidity
Safety
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts : A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO). / Schiele, T. M.; Regar, E.; Silber, S.; Eeckhout, E.; Baumgart, D.; Wijns, W.; Colombo, A.; Rutsch, W.; Meerkin, D.; Gershlick, A.; Bonan, R.; Urban, P.

In: Heart, Vol. 89, No. 6, 01.06.2003, p. 640-644.

Research output: Contribution to journalArticle

Schiele, TM, Regar, E, Silber, S, Eeckhout, E, Baumgart, D, Wijns, W, Colombo, A, Rutsch, W, Meerkin, D, Gershlick, A, Bonan, R & Urban, P 2003, 'Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts: A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO)', Heart, vol. 89, no. 6, pp. 640-644.
Schiele, T. M. ; Regar, E. ; Silber, S. ; Eeckhout, E. ; Baumgart, D. ; Wijns, W. ; Colombo, A. ; Rutsch, W. ; Meerkin, D. ; Gershlick, A. ; Bonan, R. ; Urban, P. / Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts : A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO). In: Heart. 2003 ; Vol. 89, No. 6. pp. 640-644.
@article{da29ea04750a4cab8a1390b15ad53155,
title = "Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts: A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO)",
abstract = "Objective: To assess clinically and angiographically the feasibility, safety, and effectiveness of vascular brachytherapy (VBT) in saphenous vein bypass grafts (SVG). Patients and methods: 67 of 1098 (6.1{\%}) consecutive patients of the European registry of intraluminal coronary β brachytherapy underwent treatment for 68 SVG lesions by VBT using a Sr/Y90 source train (BetaCath). Clinical follow up data were obtained for all of them after a mean (SD) of 6.3 (2.4) months and angiographic follow up was performed in 61 patients (91.0{\%}) after 6.9 (2.0) months. Results: 58 (86.6{\%}) patients were men, their mean (SD) age was 66 (10) years, 28 (41.8{\%}) had unstable angina, and 21 (31.3{\%}) had diabetes. Fifty three (77.9{\%}) lesions were in-stent restenosis, 13 (19.1{\%}) de novo lesions, and 2 (3.0{\%}) non-stented restenotic lesions. Mean (SD) reference diameter before the intervention was 4.19 (0.52) mm, mean (SD) lesion length was 23.56 (20.38) mm, and mean (SD) minimum lumen diameter measured 0.73 (0.62) mm. Mean (SD) acute gain was 3.02 (0.88) mm. The prescribed radiation dose was 20.1 (3.2) Gy. Pullback manoeuvres were performed in 17 (25.0{\%}) of cases. Most patients received combined aspirin and thienopyridin treatment for 6 or 12 months after the procedure. Technical success was obtained in 62 (91.2{\%}) treated lesions and in-hospital major adverse cardiac events occurred in 4.5{\%}. At follow up, mean (SD) reference diameter was 4.20 (0.53) mm, minimum lumen diameter 2.94 (1.50) mm, and late loss 0.86 (1.25) mm. The overall major adverse cardiac events rate was 26.7{\%}. Conclusion: VBT of SVG is feasible and safe. At follow up the reintervention rate and cardiac morbidity and mortality seem to be favourable, considering that interventions in SVG usually are associated with the highest risks.",
author = "Schiele, {T. M.} and E. Regar and S. Silber and E. Eeckhout and D. Baumgart and W. Wijns and A. Colombo and W. Rutsch and D. Meerkin and A. Gershlick and R. Bonan and P. Urban",
year = "2003",
month = "6",
day = "1",
language = "English",
volume = "89",
pages = "640--644",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical and angiographic acute and follow up results of intracoronary β brachytherapy in saphenous vein bypass grafts

T2 - A subgroup analysis of the multicentre European registry of intraluminal coronary β brachytherapy (RENO)

AU - Schiele, T. M.

AU - Regar, E.

AU - Silber, S.

AU - Eeckhout, E.

AU - Baumgart, D.

AU - Wijns, W.

AU - Colombo, A.

AU - Rutsch, W.

AU - Meerkin, D.

AU - Gershlick, A.

AU - Bonan, R.

AU - Urban, P.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective: To assess clinically and angiographically the feasibility, safety, and effectiveness of vascular brachytherapy (VBT) in saphenous vein bypass grafts (SVG). Patients and methods: 67 of 1098 (6.1%) consecutive patients of the European registry of intraluminal coronary β brachytherapy underwent treatment for 68 SVG lesions by VBT using a Sr/Y90 source train (BetaCath). Clinical follow up data were obtained for all of them after a mean (SD) of 6.3 (2.4) months and angiographic follow up was performed in 61 patients (91.0%) after 6.9 (2.0) months. Results: 58 (86.6%) patients were men, their mean (SD) age was 66 (10) years, 28 (41.8%) had unstable angina, and 21 (31.3%) had diabetes. Fifty three (77.9%) lesions were in-stent restenosis, 13 (19.1%) de novo lesions, and 2 (3.0%) non-stented restenotic lesions. Mean (SD) reference diameter before the intervention was 4.19 (0.52) mm, mean (SD) lesion length was 23.56 (20.38) mm, and mean (SD) minimum lumen diameter measured 0.73 (0.62) mm. Mean (SD) acute gain was 3.02 (0.88) mm. The prescribed radiation dose was 20.1 (3.2) Gy. Pullback manoeuvres were performed in 17 (25.0%) of cases. Most patients received combined aspirin and thienopyridin treatment for 6 or 12 months after the procedure. Technical success was obtained in 62 (91.2%) treated lesions and in-hospital major adverse cardiac events occurred in 4.5%. At follow up, mean (SD) reference diameter was 4.20 (0.53) mm, minimum lumen diameter 2.94 (1.50) mm, and late loss 0.86 (1.25) mm. The overall major adverse cardiac events rate was 26.7%. Conclusion: VBT of SVG is feasible and safe. At follow up the reintervention rate and cardiac morbidity and mortality seem to be favourable, considering that interventions in SVG usually are associated with the highest risks.

AB - Objective: To assess clinically and angiographically the feasibility, safety, and effectiveness of vascular brachytherapy (VBT) in saphenous vein bypass grafts (SVG). Patients and methods: 67 of 1098 (6.1%) consecutive patients of the European registry of intraluminal coronary β brachytherapy underwent treatment for 68 SVG lesions by VBT using a Sr/Y90 source train (BetaCath). Clinical follow up data were obtained for all of them after a mean (SD) of 6.3 (2.4) months and angiographic follow up was performed in 61 patients (91.0%) after 6.9 (2.0) months. Results: 58 (86.6%) patients were men, their mean (SD) age was 66 (10) years, 28 (41.8%) had unstable angina, and 21 (31.3%) had diabetes. Fifty three (77.9%) lesions were in-stent restenosis, 13 (19.1%) de novo lesions, and 2 (3.0%) non-stented restenotic lesions. Mean (SD) reference diameter before the intervention was 4.19 (0.52) mm, mean (SD) lesion length was 23.56 (20.38) mm, and mean (SD) minimum lumen diameter measured 0.73 (0.62) mm. Mean (SD) acute gain was 3.02 (0.88) mm. The prescribed radiation dose was 20.1 (3.2) Gy. Pullback manoeuvres were performed in 17 (25.0%) of cases. Most patients received combined aspirin and thienopyridin treatment for 6 or 12 months after the procedure. Technical success was obtained in 62 (91.2%) treated lesions and in-hospital major adverse cardiac events occurred in 4.5%. At follow up, mean (SD) reference diameter was 4.20 (0.53) mm, minimum lumen diameter 2.94 (1.50) mm, and late loss 0.86 (1.25) mm. The overall major adverse cardiac events rate was 26.7%. Conclusion: VBT of SVG is feasible and safe. At follow up the reintervention rate and cardiac morbidity and mortality seem to be favourable, considering that interventions in SVG usually are associated with the highest risks.

UR - http://www.scopus.com/inward/record.url?scp=0037809803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037809803&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 640

EP - 644

JO - Heart

JF - Heart

SN - 1355-6037

IS - 6

ER -